ReviewFrontiers in oncology2025
Research progress on the therapeutic effects of effective components of traditional Chinese medicine in the treatment of gastric cancer precursors through modulation of multiple signaling pathways.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- 8 specific Chinese herbal injections combined with chemotherapy for breast cancer: a systematic review and network meta-analysis of comparative safety and efficacy.Frontiers in pharmacology · 2025Pooled it
- Integrative management of gastric cardia cancer and precancerous lesions: prospects and mechanistic rationale for Banxia Xiexin Tang.Frontiers in pharmacology · 2026Review
- Targetable pathways for drug repurposing in gastric cancer.World journal of gastroenterology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precancerous lesions of the stomach (PLGC), a critical stage in gastric cancer development, have garnered significant attention for its prevention and treatment. PLGC refers to a series of pathological and histological changes preceding cancer. Due to its complex pathogenesis and multi-factor influence, no currently existing drug can effectively prevent or delay this process. Therefore, identifying a safe and effective treatment method remains an important research focus. In recent years, traditional Chinese medicine has demonstrated unique advantages and potential in PLGC treatment. Many studies have focused on the regulation of traditional Chinese medicine's active ingredients on relevant signaling pathways. Studies show active ingredients can regulate cell proliferation, apoptosis, differentiation, autophagy, oxidative stress, and inflammatory response via multi-target, multi-pathway intervention of key signaling pathways like hypoxia-inducible factor 1 (HIF-1α), nuclear factor kappa-B (NF-κB), wingless-type MMTV integration site family/beta-catenin (Wnt/β-catenin), phosphoinositide 3-kinases/Protein kinase B (PI3K/AKT), Sonic Hedgehog (Shh), Janus kinase/signal transducer and activator of transcription (JAK/STAT), mitogen-activated protein kinase (MAPK), nuclear factor erythroid 2-related factor 2 (Nrf2), and more, thereby delaying or reversing PLGC progression. This paper summarizes and sorts research on the regulation of these pathways by traditional Chinese medicine's active ingredients, seeking to provide a theoretical basis and medication reference for PLGC treatment with traditional Chinese medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.